-
Zenkuda (tabirafusp-ted) Meets Key Targets in Pivotal Daybreak Trial for wAMD
NASDAQ: $KOD A Major Milestone in Eye Care Recent clinical news brings a promising update for patients suffering from wet age-related macular degeneration (wAMD). The pivotal Daybreak trial has officially met its primary endpoints for Zenkuda (tabirafusp-ted), marking a significant step forward in the development of new treatment options for this sight-threatening condition. Understanding the…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…